Bioscience

Ascalon leverages experienced management team, strategic partnerships for cancer drug development

August 16, 2010

By Flinn Foundation

[Source: OneMedPlace] – Ascalon International is a privately held oncology-focused drug development company based in Scottsdale, Arizona. Ascalon was established in June 2009 to create and manage a diversified portfolio of promising oncology drugs using cutting-edge development methodologies, pioneered by the company’s management team and capitalize on the growing trend in the pharmaceutical industry for strategic outsourcing of development programs. Founders include Richard Love  (Chairman), Dr. Daniel Von Hoff (Chief Scientific Officer), Ed Jacobs (President) and others who individually and collectively have a rich history of oncology development. Dr. Von Hoff is also the Physician in Chief and Director of Translational Research at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona and  Chief Scientific Officer for U.S. Oncology.

For more information: Ascalon Leverages Experienced Management Team, Strategic Partnerships for Cancer Drug Development